CompletedPhase 4

Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients

Egypt60 participantsStarted 2022-01-04

Plain-language summary

Prospective phase IV interventional open label randomized controlled trial to assess safety and efficacy of glutamine in preventing vaso-occlusive crisis (VOC) episodes in sickle cell pediatrics and adolescents' patients

Who can participate

Age range2 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Children and adolescents diagnosed with sickle cell disease by haemoglobin electrophoresis and had at least two pain crises (no upper limit) documented during the previous year; a pain crisis is defined as pain leading to treatment with a parenteral administered narcotic or ketolac in an emergency department (ED) (or outpatient treatment centre) or during hospitalization. Patients receiving hydroxyurea at a fixed dose for at least 3 months before screening. Exclusion Criteria: Patients with sickle cell trait and other hemoglobinopathy. \-

What they're measuring

Number of pain crises

Timeframe: 24 weeks

Trial details

NCT IDNCT05371184

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-03

View on ClinicalTrials.gov More Sickle Cell Disease trials